Giving Life to Science®

We are dedicated to changing the treatment landscape for patients with devastating diseases

Explore Programs

Unlocking the Potential of Validated Pharmacology

We do this by improving tolerability, enabling oral administration or enhancing on-target efficacy to unlock new classes of medicine

Strong track record of success has now generated

27 therapeutics and therapeutic candidates

17 are clinical stage

2 granted FDA clearance & European marketing authorization and a third that will soon be filed for FDA approval

See Our Programs

Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals

Meet Our Global Collaborators

Our seasoned senior leadership team oversaw R&D of therapeutics supporting 26 regulatory approvals and served in the C-suite of companies acquired for more than $14B in aggregate

Meet Our Team
Publications
ALL >
Internal Pipeline
PureTech's Lymphatic Leap

FULL ARTICLE

Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Vedanta
Science: The Gut’s Clostridium Cocktail

Full Article

Press releases
2022-08-09
PureTech to Receive up to Approximately $115.4 Million from Sale of a Portion of Founded Entity Shares
Press releases
2022-08-08
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
Press releases
2022-08-04
Notice of Half-Yearly Results